Literature DB >> 31494036

CDK4/6 inhibitors: taking the place of chemotherapy?

Azadeh Nasrazadani1, Adam M Brufsky2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31494036     DOI： 10.1016/S1470-2045(19)30507-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis.

Authors:  Qiancheng Hu; Wenli Kang; Qingfeng Wang; Ting Luo
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

2.  CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal.

Authors:  Lisa Crozier; Reece Foy; Brandon L Mouery; Robert H Whitaker; Andrea Corno; Christos Spanos; Tony Ly; Jeanette Gowen Cook; Adrian T Saurin
Journal:  EMBO J       Date:  2022-01-17       Impact factor: 14.012
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.